利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

17 条记录 (耗时 0.033 秒)

    POLYMERIC CARRIER CARGO COMPLEX FOR USE AS AN IMMUNOSTIMULATING AGENT OR AS AN ADJUVANT
    3.
    发明申请
    POLYMERIC CARRIER CARGO COMPLEX FOR USE AS AN IMMUNOSTIMULATING AGENT OR AS AN ADJUVANT 有权

    公开(公告)号：US20210361764A1

    公开(公告)日：2021-11-25

    申请号：US17393362

    申请日：2021-08-03

    申请人： CureVac AG

    发明人： Mariola FOTIN-MLECZEK ,  Regina HEIDENREICH

    IPC分类号： A61K39/385 ,  A61K47/64 ,  A61K39/12 ,  A61K39/145 ,  A61K39/155 ,  A61K39/205 ,  C12N7/00 ,  C12N15/117

    摘要： The present invention is directed to a polymeric carrier cargo complex, comprising as a cargo at least one nucleic acid molecule and as a preferably non-toxic and non-immunogenic polymeric carrier disulfide-crosslinked cationic components for use as an immunostimulating agent or as an adjuvant, wherein the polymeric carrier cargo complex is administered in combination with at least one second nucleic acid molecule, which encodes a protein or peptide. The inventive polymeric carrier cargo complex administered in combination with the second nucleic acid molecule allows for both efficient transfection of nucleic acids into cells in vivo and in vitro and/or for induction of an innate and/or adaptive immune response, preferably dependent on the nucleic acid to be transported as a cargo and on the second nucleic acid molecule. The present invention also provides pharmaceutical compositions, particularly vaccines, comprising the inventive polymeric carrier cargo complex and the second nucleic acid molecule, as well as the use of the inventive polymeric carrier cargo complex and the second nucleic acid molecule for transfecting a cell, a tissue or an organism, as a medicament, for therapeutic purposes as disclosed herein, and/or as an immunostimulating agent or adjuvant, e.g. for eliciting an immune response for the treatment or prophylaxis of diseases as mentioned herein. Finally, the invention relates to kits containing the inventive polymeric carrier cargo complex and the second nucleic acid molecule, the inventive pharmaceutical composition and/or the inventive vaccine or any of its components in one or more parts of the kit.

    OPTIMIZED NUCLEIC ACID MOLECULES
    7.
    发明申请
    OPTIMIZED NUCLEIC ACID MOLECULES 审中-公开

    公开(公告)号：US20180312545A1

    公开(公告)日：2018-11-01

    申请号：US15774423

    申请日：2016-11-09

    申请人： CureVac AG

    发明人： Patrick BAUMHOF ,  Susanne RAUCH ,  Aleksandra KOWALCZYK ,  Johannes LUTZ ,  Edith JASNY ,  Benjamin PETSCH ,  Andreas THESS ,  Thomas SCHLAKE ,  Mariola FOTIN-MLECZEK ,  Regina HEIDENREICH ,  Sandra LAZZARO ,  Fatma DÖNER ,  Wolfgang GROSSE

    IPC分类号： C07K14/005 ,  C07K14/205 ,  A61K39/145

    CPC分类号： C12N15/00 ,  A61K39/12 ,  A61K2039/53 ,  C07K14/005 ,  C07K2319/00 ,  C12N2760/16122 ,  C12N2760/16134

    摘要： The present invention provides optimized nucleic acid molecules, methods for optimization of nucleic acid molecules and uses of optimized nucleic acid molecules. A modular design principle is provided that is suitable to generate a nucleic acid, particularly mRNA, which is tailored for a respective application. The nucleic acid molecules of the present invention can be obtained by the versatile combination of multiple modules on nucleic acid level. Such nucleic acid, e.g. mRNA, can be tailored by combining one or more modules, comprising (i) a nucleic acid moiety encoding a polypeptide of interest (e.g. a protein potentially producing a therapeutic outcome) and (ii) at least one further coding or non-coding nucleic acid moiety, e.g. selected among nucleic acid moieties encoding a polypeptide element, such as a secretory signal peptide (SSP), a multimerization element (dimerization, trimerization, tetramerization and oligomerization), a virus like particle (VLP) forming element, a transmembrane element, a dendritic cell targeting element, an immunological adjuvant element, an element promoting antigen presentation; a 2A peptide; a peptide linker element, elements that extend protein half-life, and/or any other polypeptide or protein. Non-coding nucleic acid moieties may be selected e.g. from the group comprising 3′-UTR, 5′-UTR, IRES element, miRNA moiety, histone stem loop, poly(C) sequence, polyadenylation signal, polyA-sequence. The optimized nucleic acid molecule can further be characterized by the presence of at least one modified nucleoside. The versatility of the present invention allows for rational design of a large variety of different nucleic acid molecules with desired properties.

    NOVEL YELLOW FEVER NUCLEIC ACID MOLECULES FOR VACCINATION
    10.
    发明申请
    NOVEL YELLOW FEVER NUCLEIC ACID MOLECULES FOR VACCINATION 有权

    公开(公告)号：US20210361761A1

    公开(公告)日：2021-11-25

    申请号：US17045236

    申请日：2019-04-05

    申请人： CureVac AG

    发明人： Johannes LUTZ ,  Susanne RAUCH ,  Regina HEIDENREICH ,  Benjamin PETSCH

    IPC分类号： A61K39/12 ,  C12N7/00 ,  A61K9/51

    摘要： The present invention is directed to an artificial nucleic acid, particularly to an artificial RNA suitable for use in treatment and/or prophylaxis of an infection with yellow fewer vims (YFV) or a disorder related to such an infection. The invention further concerns a method of treating or preventing a disorder or a disease, first and second medical uses of the artificial RNA, compositions and vaccines. Further, the invention is directed to a kit, particularly to a kit of parts, comprising the artificial RNA, compositions and vaccines.